

LODOCO – Colchocine Research

Mark Nidorf Chairs: Craig Cheetham, Paul Camp

Colchicine for 2° Prevention of Cardiovascular Disease

LoDoCo2 - An Australian-Dutch Collaboration




Atherosclerosis is the Major Cause of Heart-Attack Stroke and Sudden Death in the Western World

Bypass & PTCA may improve short term symptoms in some patients Neither of these interventions halt the progression of the disease Both create new problems in of themselves

The only way to improve the long-term outcome of patients with atherosclerosis is to alter the underlying *processes* that drive the disease

The Process of Atherosclerosis Can Be Modified by Lowering LDL in a Dose Dependent Manner



The PCSK9 Trials will determine if there is a limit to the benefits of lowering LDL

The Current Paradigm for 2° Prevention of Atherosclerosis Does <u>Not</u> Directly Target the Disease Process

Lowering LDL To reduce the fuel for the inflammatory fire

Anti-platelet therapy

To prevent thrombosis resulting from failure to prevent inflammatory injury


Cholesterol Core Bound -> Free -> Crystals

Athero-Thrombosis

Inflammation Repeated Injury-Healing Plaque Growth or Disruption


To Modify the Natural History of Atherosclerosis we Need to Modify all of the Processes that Drive it

The Arterial Wall is Aflame With Activity




The Next Frontier in the Treatment of Atherosclerosis

The promise that targeting the underlying inflammatory & healing processes in atherosclerotic plaque will improve clinical outcomes



Drugs to inhibit Mediators of Chronic Healing Slow growth of SM cells, Fibrocytes, Osteocytes

Therapies Must Target a Number of Processes



Well tolerated, safe over decades, affordable & readily available

The Journey into the Use of Colchicine for 2° Prevention of Cardiovascular Disease





Colchicine

Uses

Therapeutic use of >2000 years

Recognized as an effective treatment for acute pericarditis

Long-term use is highly effective for 2° prevention of gout & FMF

Actions

Taken up rapidly & avidly by Macrophages & Neutrophils **Prevents & Dampens IL-1** β release & Dampens Neutrophil function **Promotes favourable healing** by reducing the growth of vascular smooth muscle cells, fibrocytes & osteophytes




Continuous Use of Low Dose Colchicine is Safe

Long-term daily doses of up to 2mg/d is FDA approved [FMF] 5-10% experience mild early GI effects - dose related* Myo-, BM toxicity & Death limited to cases of intentional over-dose It has no detrimental effects on renal or hepatic function** Serious drug interactions are limited - Clarithromycin***

* 98% tolerate 0.25mg/day
** Used in advanced renal failure and cirrhosis
*** Nexium 7



Given its Relevant Biologic Effects & Proven Safety Long-Term Colchicine May Improve the Clinical Outcome of Patients with Stable Coronary Artery Disease






When Clinicians take their Ideas from Bench to Bedside it Requires a Leap of Faith

... they need to go forward aware of uncertainties but 'in the confident hope of a miracle'*

* Admiral Martin de Bertendona, Commander of the [Spanish Armada] Levant squadron Expressing doubts about the chances of success of the invasion of England



Colchicine Can Rapidly Reduce Inflammation [hs-CRP] in Pts with Stable Coronary Disease over Aspirin & Statins




Nidorf SM etal. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. *Am J Cardiol* 2007;99:805-7

If Colchicine can reduce hs-CRP can it improve clinical outcome?



LoDoCo Trial The Effect of Colchicine for 2° Prevention of CVD 1st trial to support the potential of anti-inflammatory in IHD



Nidorf SM etal. Low-dose colchicine for secondary prevention of cardiovascular disease JACC 61;2013: 404 - 406



Low Dose Colchicine has been demonstrated to:

Limit plaque growth & stent re-stenosis in animal studies Reduce hs-CRP, IL-6, IL-1β in pts with stable & unstable CAD Reduce the extent of in-stent stenosis in diabetics with bare stents Reduce myocardial reperfusion injury post AMI & CABG

Added support for its potential for 2° prevention in CAD


2 Meta-analyses Colchicine in pts <u>+</u> CV Disease reduced risk of AMI & CV Death
2 Retrospective cohort studies in patients with gout

Colchicine for prevention of cardiovascular events. Cochrane Database_ 2016 Jan

Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, et al. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC cardiovascular disorders. 2015;15(1):1



Patients With Gout who Receive Colchicine are Less Likely to Suffer a CV Event




Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims Daniel H Solomon, **annrheumdis-2015**

Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. Crittenden DB The Journal of rheumatology 2012;39:1458-64.



Colchicine May Fulfil Many of the Requisites for 2° Prevention of Atherosclerosis




Well tolerated, safe over decades, affordable & readily available



Whilst LoDoCo1 'put Colchicine on the Map' LoDoCo2 will Confirm its Place in the World



Ongoing Trials of Low Dose Colchicine in CV Disease



The LoDoCo2 Trial Initiated by the Cardiologists in this Practice in association with The Heart Research Institute of WA, Ethics approval from Sir Charles Gairdner Hospital and with generous support from GenesisCare.

The LoDoCo2 Trial

~4,000 Pts with <u>Stable</u> CAD
WA & Netherlands
Began August 2014 - WA >85% recruited

COLCOT Colchicine Cardiovascular Outcome Trial ~3,000 Pts Post ACS Montreal Heart Canada Began Dec 2015

~ 7,000 people with coronary disease will be recruited to a LoDoCo type trial



CLINICAL TRIAL

IF YOU HAVE CORONARY DISEASE

you may be eligible to take part in our innovative clinical research



The LoDoCo2 Trial Initiated by the Cardiologists in this Practice in association with The Heart Research Institute of WA, Ethics approval from Sir Charles Gairdner Hospital and with generous support from GenesisCare.


The LoDoCo2 Trial

- Prospectively Randomized Double Blinded Placebo Controlled Trial of 0.5mg/d Colchicine in people with stable coronary disease
- Event driven outcome Mean follow up 3 years
- To confirm efficacy and safety of LD colchicine for 2° Prevention
- Initiative from the Cardiologists within HCWA No conflicts of interest
- Aspen Pharma have supplied active & placebo at no cost
- HRI supported application for Ethics & Governance via QEII
- Recruitment began in August 2014
- NHMRC Funding Approved November 2014
- Now to be strongly supported with a bolus recruitment effort by WCN

[ACTRN12614000093684 -ANZCTR]



The Low Dose Colchicine Trial (LoDoCo2)





DO YOU HAVE CORONARY DISEASE?

Ask your Cardiologist if you are eligible to take part in the next phase of our innovative clinical research into the possible prevention of Heart Attacks and Strokes



Low-dose colchicine for secondary prevention of cardiovascular disease. Nidorf SM, Ekelboom JW Budgeon CA, Thompson PL. Journal of the American College of Cardiology. 612013:404-406. February 201-

Whe illest husballs

The LoDoCo2 Trial

Initiated by the Cardiologists in this Practice in association with The Heart Research Institute of WA, Ethics approval from Sir Charles Gairdner Hospital and with generous support from Genesis Care. GenesisCare

day Tawashes 6, 2012		REIIO 3
out medication reduces risk of heart attack		
Next Assistration-lead outdy have end a preventy risk of heart wick could be diversalizedly lacent by taking a common distation to trease grow. I More these SOD people outputed in the Haratt march institute analysist this Sir Charles Querther pipela Some serve given the g Collections. Loost Loost reasoned by There ompoon ways the results are y moving.	When we give the drug is the patients compared with those who also are couries the drug the nat. of hear stands of the second stands are stand effects were more stands that are any stand recer desided stations are yet accorded to the hear does not no second or summary and recer desided stations are yet accorded to the hear does not no second or summary and recer desided stations are yet accorded to the hear any station of the second tensor of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the second of the	beart disease in treated around the world. "This is a drug which is relatively incorporate and downsive efforts and drug drug are bring trialited and developed has they are quing trialited and studyed at they are quing trialited and studyed at they are quing trialited and studyed at they are quing trialited and studyed studyed and and studyed at the study studyed and studyed at the studyed studyed and studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed at the studyed at the studyed at the studyed studyed at the studyed studyed at the studyed studyed at the studyed studyed studyed at the studyed studyed at the studyed stu

MENO I

Success relates to

The ability to rapidly recruit a large number of pts*

The ability to embed complex trial logistics into the everyday routines in the Practice

Driven and Engaged Doctor Group

Dedicated Staff

* If WCN can effect a rapid bolus recruitment LoDoCo2 could be fully recruited in 6m




Integration the LoDoCo2 Trial into the Practice

- 1] All clinics are **pre-screened** a week in advance
- 2] Suitable patients are identified by colour code on the day list This allows patients to be identified as they come into the Practice <u>Reception staff</u> hand over reading material before they are seen
- 3] <u>Cardiologist</u> talk to the trial and prepare for consent [note in record]
- 4] Signed consent forms taken by <u>secretaries</u> who provide open label TM This process is logged to ensure all TM stock is accounted for Patients given written instructions about dosing



Recruitment & Randomization into LoDoCo2

1 Practice - **10** Recruiting Cardiologists




* 20% drop out before randomization

10% Unwilling some because they were keen not to be denied colchicine
10% Early Intolerance – 95% GI - bloating, reflux, diarrhoea, constipation, 5% other
>85% of these pts (98% of all pts) tolerate 0.25mg, and some go on to tolerate 0.5mg



Is LoDoCo2 going to be Relevant in the New World of PCSK9 Inhibitors & Canakinumab





Absolutely YES

Lowering LDL Will Never Completely Dampen the Inflammatory Flame

CANTOS is +ve So There Will Be Intense Interest in Colchicine

Because it implies that the IL-1 β pathway is important but leaves open the question as to how best to block it

Colchicine Like Canakinumab targets the IL-1β pathway

Colchicine <u>Unlike</u> Canakinumab;

Also targets the chronic healing responses to inflammatory injury Is inexpensive and widely available Is well tolerate - 90% tolerate 0.5mg/d & 98% tolerate 0.25mg/d Has proven long-term safety over decades even at higher dose